Cancer Institute A national cancer institute
designated cancer center

Our Team

Stanford's multidisciplinary team of urologic cancer experts includes medical oncologists, surgical oncologists, radiation oncologists and genito-urinary pathologists. Our physicians have extensive experience treating routine to advanced cases of all types of urologic cancers.

Eila C. Skinner, MD Eila C. Skinner, MD
Professor and Chair
Thomas Stamey Research Professor of Urology

Dr. Eila Skinner is a urologic oncologist with extensive experience in the treatment of urologic cancers, including bladder, testis, prostate and kidney. Her primary focus has been in the surgical treatment of locally advanced bladder cancer and is a nationally recognized expert in bladder reconstruction and continent urinary diversion. She also tackles complex surgical problems, including resection of retroperitoneal masses associated with testis cancer and locally extensive kidney cancers. Dr. Skinner graduated from Stanford University and obtained her medical training from Keck USC School of Medicine. She completed a residency in Urology at LAC+USC Medical Center, and a fellowship in Urologic Oncology under Dr. Donald Skinner at the Norris Cancer Center at USC. She was on the faculty at USC from 1990 through 2012. She was recruited to Stanford University to become Chair of the Department of Urology in May 2012. Dr. Skinner has received a number of awards including a Stop Cancer career development award, numerous teaching awards and listing in “Best Doctors” for over a decade. She has active ongoing clinical trials in the treatment of bladder cancer and other urologic malignancies.

James Brooks, MD James Brooks, MD
Keith and Jan Hurlbut Professor of Urology
Chief of Urologic Oncology
Urologic Oncology Surgeon

Dr. James D. Brooks is an internationally recognized expert in prostate cancer. He received his undergraduate degree from the University of Chicago and his medical degree from Stanford. He completed his urology residency and his urologic oncology fellowship training at Johns Hopkins Hospital. Dr. Brooks has made major contributions to understanding the molecular genetic causes of prostate cancer and had published and lectured extensively on prostate cancer. He is the recipient of numerous awards, including the Dornier Research Scholar Award, the Doris Duke Foundation Clinical Research Scientist Award, the Eugene Schoenfeld Award, the Leutje-Stubbs Faculty Scholar Award and is included in several “Best Doctors” rankings. He is the Editor-in-Chief of The Open Prostate Cancer Journal, and he serves on the editorial boards of Prostate Cancer, Andrology, Scientifica, and The Prostate. He is Co-Chair of the Prostate and Urologic Cancers Group in the Early Detection Research Network of the NIH and serves as a member of the Prostate Cancer Research Program Integration Panel for the Department of Defense. His practice focuses on prostate cancer detection, risk assessment, active surveillance and surgical management using traditional and robotic approaches.


Mark K. Buyyounouski, MD, MS Mark K. Buyyounouski, MD, MS
Associate Professor
Director, Genitourinary Cancers
Department of Radiation Oncology

Mark K. Buyyounouski, MD, MS, is Associate Professor and Director of Genitourinary Cancers, Department of Radiation Oncology at Stanford University School of Medicine.

Dr. Buyyounouski received his medical degree from New Jersey Medical School and completed his internship at Saint Barnabas Medical Center. He completed his residency in radiation oncology at Fox Chase Cancer Center.

Dr. Buyyounouski specializes in external beam radiotherapy and brachytherapy for prostate cancer, and other types of genitourinary cancers such as cancers of the testes and bladder. He joins Stanford from Fox Chase Cancer Center in Philadelphia, PA, where he was Associate Professor and Director of Clinical Research.

His research interests include: genitourinary cancers, definitive and salvage radiotherapy, permanent low dose rate (LDR) and temporary high dose rate (HDR) prostate brachytherapy, intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), stereotactic body radiotherapy (SBRT) and translational applications of MRI for the detection and treatment of prostate cancer.  Dr. Buyyounouski’s clinical research has focused on helping men preserve erectile function following radiation therapy for prostate cancer and combination radiotherapy with immunotherapy for intermediate and high-risk prostate cancer patients.

Dr. Buyyounouski has received the Roentgen Resident/Fellow Research Award twice from the Radiological Society of North America and the Young Investigator award in 2005 from the American Society for Radiation Oncology. He has co-authored over 70 peer-reviewed scientific publications, numerous book chapters, and editorials on prostate cancer, IMRT, and testicular cancer.

Dr. Buyyounouski is a principal investigator for the Radiation Therapy Oncology Group (RTOG), Chairperson of the Committee for Evidence-Based Brachytherapy for the American Brachytherapy Society (ABS); and Editor of the International Journal of Radiation Oncology, Biology, and Physics and Brachytherapy medical journals. He is also Vice-Chair of the Emerging Technology Committee of the Health Policy Council of the American Society for Radiation Oncology (ASTRO). Dr Buyyounouski is also heavily involved in education as a Member of the Genitourinary Committee of the American Board of Radiology (ABR). 

Benjamin Chung, MD Benjamin Chung, MD
Urologic Oncologist
Assistant Professor of Urology
Director of Minimally Invasive Urologic Surgery
Dr. Benjamin Chung has achieved national recognition for his expertise in minimally invasive treatments in the treatment of prostate cancer and kidney cancer and he has one of the largest experiences of both robotic radical prostatectomy and robotic partial nephrectomy in the region.

He recieved his undergraduate degree at Amherst College and his medical degree at Jefferson Medical College. Thereafter, he completed his internship and general surgery training in the Department of Surgery at Massachusetts General Hospital and completed his residency in the Department of Urology at the Lahey Clinic. Dr. Chung then received advanced fellowship subspecialty training in robotic and minimally invasive urologic surgery in the Department of Urology at the Cleveland Clinic.

He has served as a speaker both nationally and internationally with the National Comprehensive Cancer Network (NCCN) on the treatment and outcomes of kidney cancer and the benefits of nephron sparing techniques, where just the cancer is removed and the kidney is spared. He has also been featured on the Discovery Health Network as an expert on surgical treatments of kidney cancer.

He is currently in the midst of obtaining a Masters degree in Epidemiology at Stanford to hone his research interests of environmental and other associated factors that cause prostate cancer and kidney cancer. In addition, his current research involves large scale database analyses utilizing both national and international collaborations examining robotic surgical outcomes and robotic adoption in urologic cancer surgeries.


Harcharan Gill, MD Harcharan Gill, MD
Urologic Oncologist
Dr. Gill is well recognized for his clinical skills in urologic oncology. He received his medical degree from the University of Nairobi, Kenya, following which he completed a general surgery residency at the Royal College of Surgeons in Dublin. He followed this with a urology residency at the British Institute of Urology in London, and the University of Pennsylvania. Dr Gill focuses on all aspects of surgical treatment of urologic malignancies and is experienced in both open and minimally invasive surgery including robotic surgery. He has published on many facets of urologic oncology. He is currently collaborating with radiologists to further study and evaluate image guided (MRI) treatments for prostate cancer. Dr Gills practice also focuses on benign prostatic hyperplasia (BPH) and he offers all minimally invasive therapies for this condition. He is also involved in developing and studying new minimally invasive devises for the treatment of BPH.

Steven Hancock, MD Steven Hancock, MD
Radiation Oncologist

Russell Pachynski, MD Russell Pachynski, MD
Medical Oncologist

Dr. Russell Pachynski completed his undergraduate work at Stanford, graduating with a B.S. in Biology with an emphasis on immunology and oncology. While an undergraduate, he began his research career at UCLA and subsequently Genentech, Inc, where he worked on what eventually became Herceptin (trastuzumab). Following his undergraduate degree, he began his training in basic immunology under the mentorship of Dr. David Erle at UCSF. There, he studied the structure and function of integrins - a class of molecules involved in cell adhesion. He also performed some of the early studies characterizing the function of CCL21 (or SLC - secondary lymphoid tissue chemokine), and published one of the first descriptions of a chemokine triggering leukocyte adhesion through integrins under shear flow. He then attended medical school at the University of Wisconsin-Madison. While a medical student, Dr. Pachynski was chosen as a Howard Hughes-National Institutes of Health (NIH) Research Scholar. He spent over a year at the National Cancer Institute under the mentorship of Dr. Patrick Hwu and Steven Rosenberg in the Surgery Branch studying mouse models of melanoma. His work there focused on redirecting the immune system and targeting white blood cells to traffic to tumors more effectively. For his work, he was awarded the prestigious Howard Hughes Medical Institute Continuing Fellowship Award. He then returned to Stanford to complete his internship and residency training in Internal Medicine. He completed the Stanford ABIM Research Pathway and entered Oncology fellowship at Stanford. During fellowship, he focused on prostate cancer in the clinic and continued to work on mouse models of immunotherapy while in the lab. He has won numerous awards for his work, and continues to investigate the mechanisms of leukocyte trafficking in the setting of tumor immunosurveillance and immunity. Clinically, he specializes in prostate cancer and has been an investigator on numerous trials, with an emphasis on prostate cancer immunotherapy and translational cutting edge research.


Geoffrey Sonn, MD Geoffrey Sonn, MD
Assistant Professor of Urology and Radiology (by courtesy)

Dr. Geoffrey Sonn is a urologic oncologist with experience in the minimally invasive treatment of urologic cancers. He received his undergraduate degree from Georgetown University and his medical degree from UCLA. He completed his Urology residency training at Stanford and urologic oncology fellowship at UCLA where he received subspecialty training in the open and robotic management of prostate, kidney, bladder, and testicular cancer.  

During his fellowship training, he developed expertise in MRI-ultrasound fusion targeted biopsy, a cutting-edge tool to improve prostate cancer diagnosis that identifies potentially lethal cancers more accurately than conventional biopsy methods, enabling personalized treatment decisions for men with prostate cancer.

Dr. Sonn’s clinical focus is the treatment of patients with urologic cancers with a particular interest in prostate and kidney cancer. In his surgical practice, Dr. Sonn emphasizes the use of minimally invasive technologies including targeted biopsy, robotic surgery and image-guided focal therapy.

In addition to clinical practice, Dr. Sonn is committed to the development of novel imaging and focal cancer ablation techniques. His research has been published in various scientific journals, including the Journal of Urology, European Urology and Cancer.  Dr. Sonn serves as a reviewer for the Journal of Urology, Critical Reviews in Oncology/Hematology, and Urology. He is a member of the American Urological Association, a candidate member of the Society of Urology Oncology, and a member in training of the American Society of Clinical Oncologists.


Sandhya Srinivas, MD Sandhya Srinivas, MD
Medical Oncologist

Sandy Srinivas is a nationally recognized medical oncologist with clinical expertise in urologic cancers. She received a medical degree from Madras India and completed her training in internal medicine in Rocahester, NY and her oncology training at UCSF. Dr Srinivas in addition to her excellence in clinical care, has extensive clinical trial experience and has been an investigator in many national trials. She has published extensively in the field of genito urinary oncology and is a considered a leader in this field. She is passionate about teaching and has received several teaching awards at Stanford. Nationally, she sits on the NCCN panel which sets forth guidelines for management of prostate cancer.

Stanford Medicine Resources:

Footer Links: